Dr. D. R. Krishna

Chief Scientific Officer, Board Member

Therapeutic Areas

Drug	Indication	Phase
Innovation Portfolio (505(b)(2))	Oncology (specifics undisclosed)	Pre-clinical
Generic Portfolio (Complex Generics)	Not Applicable (Generic)	Pre-ANDA